On a hot streak, GSK has won a third high-profile FDA approval in recent weeks, this time for the second lung cancer drug from the British pharma’s $10.6 billion acquisition of Nuvalent earlier this year.
Marking just the second commercial lung cancer drug in GSK’s history, the FDA has cleared Nelkarmi, or neladalkib, for previously treated ALK-positive non-small cell lung cancer (NSCLC).
Compared with the company’s first lung cancer approval, gained in July for legacy Nuvalent’s Jideytro in ROS1-positive NSCLC, Nelkarmi targets a larger patient population and carries greater commercial potential. When Royalty Pharma acquired a royalty interest in the two drugs at the end of 2025, it cited analysts’ consensus sales projections of $3.5 billion for Nelkarmi by 2035, versus $1.9 billion for Jideytro.
ALK-positive patients account for about 4% of NSCLC cases, Hesham Abdullah, M.D., GSK’s global head of oncology R&D, told reporters during a press briefing. By comparison, ROS1-positive NSCLC represents an estimated 1% to 2% of NSCLC cases.
As is the case with Jideytro in ROS1-positive tumors, Nelkarmi is also launching into a competitive ALK market. Among existing therapies, Roche’s Alecensa and Pfizer’s Lorbrena, both blockbusters by 2025 sales, represent Nelkarmi’s biggest rivals.
For now, the accelerated approval for Nelkarmi only covers patients who have previously received Alecensa or at least two ALK inhibitors and platinum-based chemotherapy.
Nelkarmi’s approval arrived ahead of the FDA’s original target decision date of Nov. 27, leveraging data from the phase 1/2 Alkove-1 trial. In the study, among second-line patients who had received Alecensa as their first-line treatment, Nelkarmi achieved an overall response rate (ORR) of 49%, with 52% of responses lasting at least a year. For those who had tried two or more prior ALK drugs and chemotherapy, the ORR was 32%, with 51% of responses lasting at least one year.
Among patients with measurable brain metastases, intracranial ORRs were 55% and 26% in the two subgroups, respectively. Complete response rates were 25% and 11%, respectively.
However, when the data were presented at the ASCO 2026 annual meeting this summer, invited discussant Angel Qin, M.D., of the University of Michigan, labeled Nelkarmi’s 26% ORR in post-Lorbrena patients “modest,” causing some investor unease.
While Qin approached the data from a post-Lorbrena angle, Nuvalent management argued at the time that the “modest” language should not be applied to a comparison between Lorbrena and Nelkarmi, according to a June 5 Jefferies note. Among previously treated patients who had not received Lorbrena, Nelkarmi achieved a median progression-free survival of 14.5 months, which represents two to three times Lorbrena’s performance in a comparable second-line setting, Jefferies noted, citing Nuvalent’s response.
At least GSK was not deterred by the “modest” comment. The British pharma unveiled its $10.6 billion deal for Nuvalent days after the ASCO presentation.
GSK also believes that Nelkarmi could differentiate itself from existing options on tolerability. Pfizer’s Lorbrena is known to cause neurological side effects that may disrupt treatment.
Nelkarmi was designed with improved specificity for ALK while sparing the TrkB kinase to minimize central nervous system (CNS) side effects. Because ALK-positive NSCLC often affects younger patients, including those in their 40s and 50s, tolerability is a key treatment consideration, GSK’s Abdullah said during the press briefing.
Jefferies analysts have called Nelkarmi’s CNS tolerability profile “highly favorable,” with no cognitive or mood effects. In Alkove-1, adverse reactions led to permanent discontinuation of Nelkarmi in 5% of patients, with liver toxicity the leading cause.
“As patients move through multiple therapies over the course of their disease, they need options that balance durable disease control with the ability to tolerate and remain on treatment and maintain quality of life,” Kirk Smith, president of patient organization ALK Positive, said in a statement provided by GSK. “Today’s approval represents important progress for our community.”
An ALK drug’s safety profile is even more important in the first-line setting, as patients may stay on treatment for years. In Pfizer’s phase 3 Crown trial pitting Lorbrena against the New York pharma’s first-generation ALK inhibitor, Xalkori, in first-line ALK-positive NSCLC, patients treated with Lorbrena had a 55% likelihood of remaining alive without disease progression at seven years, according to an update presented at ASCO 2026.
GSK is testing Nelkarmi in the first-line Alkazar trial, which uses Roche’s Alecensa, a second-generation ALK inhibitor, as the comparator. Despite the growing popularity of Lorbrena as a third-generation option, Alecensa is still being used in about 45% of first-line patients, Abdullah noted.
Alecensa also boasts an FDA nod as an adjuvant treatment following tumor resection in patients with early-stage ALK-positive NSCLC. Abdullah said GSK will also consider Nelkarmi’s potential in earlier-stage disease.
Nelkarmi is the third in a string of high-profile regulatory wins for GSK in recent weeks. On Oct. 19, the FDA approved the company’s PD-1 inhibitor Jemperli as the first immunotherapy for stage 2 and 3 locally advanced rectal cancer that is microsatellite instability-high or mismatch repair deficient. The following day, the agency greenlit GSK’s Hibsago as the first antisense oligonucleotide to treat chronic hepatitis B.